Amyotrophic lateral sclerosis (ALS)

Amyotrophic lateral sclerosis (ALS)

DisruPep is starting in vitro studies and lead compound of our DR004 candidate.

Keep in touch for future advances in our peptide for ALS

Close-up of young woman at wheelchair in hospital.

Discuss With Us For Your Research Needs

Dr. Mariano Carrión Vázquez
Dr. Ismael San Mauro Martín

Main office and lab - Instituto Cajal (CSIC)

Avenida del Dr. Arce, 37, 28002 Madrid

Follow My Social Media :

 

Dont like Filling up forms ? Mail us then

Data controller: Disrupep s.l., responsible for this website Purpose of the data: Manage the request you make in this contact form. Data storage: Database hosted on siteground spain sl Rights: At any time you can limit, recover and delete your information. For more information: Privacy Policy